Background
==========

Changes in societies and lifestyles have increased the proportion of people with sub-optimal health \[[@b1-medscimonit-24-9259]\] and lead to sleep disorders and mental anxiety; middle-aged and young people are particularly affected, due to pressures at work. The lack of high-quality sleep over a long period of time causes anxiety, fatigue, pessimism, and other mental problems. Studies have revealed that lack of sleep can result in abnormal hormone secretion, weakened immunity, neuroendocrine disorders, hypersecretion of angiotensin II, and in high blood pressure \[[@b2-medscimonit-24-9259]--[@b4-medscimonit-24-9259]\]. In addition, obstructive apnea syndrome has been identified to trigger hypertension and affect the corresponding treatment \[[@b5-medscimonit-24-9259]\]. In this study we investigated changes in blood pressures and levels of inflammatory cytokines in patients with intractable insomnia and hypertension, as well as the role of chronic intractable insomnia in hypertension.

Material and Methods
====================

Study objects
-------------

We enrolled a total of 248 hypertensive patients, including 124 in the control group and 124 in the treatment group, according to the symptom of insomnia, in this study. Patients in the control group had no chronic insomnia and received antihypertensive treatment with eplerenone (50 mg), while patients in the treatment group suffered from chronic intractable insomnia and were administered with estazolam to improve their sleep quality based on the same antihypertensive treatment as the control group. Gender, age, and blood pressure of the 2 groups of patients were comparable (P\>0.05). This study was pre-approved by the Ethics Committee of our hospital. All subjects signed the informed consent forms before recruitment in this study.

Research methods
----------------

The diagnosis of hypertension was based on the Guidelines for the Prevention and Treatment of Hypertension in China \[[@b6-medscimonit-24-9259]\]. The Chinese Classification of Mental Disorders and Diagnostic Criteria \[[@b7-medscimonit-24-9259]\] was used for the diagnosis of chronic intractable insomnia. The Sleep Dysfunction Rating Scale (SDRS) was used to score intractable insomnia in patients. SDRS scoring was performed for patients in the control and treatment groups at the beginning of admission. Blood pressure was measured using a 24-h ambulatory blood pressure monitor and the levels of serum inflammatory cytokines were detected. At 0, 7, 14, 21, and 28 d after drug treatment, SDRS scores, mean systolic blood pressure (SBP), mean diastolic blood pressure (DBP), and levels of serum inflammatory cytokines in patients were recorded, and the effects of drug treatment on blood pressure treatment and sleep improvement statuses were observed.

Index monitoring
----------------

Blood pressures and serum inflammatory cytokines, SDRS scores, and blood pressure rhythm before and after treatment were observed, and 24-h SBP and SDP were monitored. Mean nighttime blood pressure/mean daytime blood pressure \>10% represents dipper blood pressure rhythm; otherwise, it is recognized as non-dipper blood pressure rhythm. SDRS scoring was conducted for sleep quality assessment. Score reduction ratio=1 minus total score after treatment/total score for baseline: ≥0.5 is effective whereas \<0.5 is ineffective.

Statistical analysis
--------------------

Statistical Product and Service Solutions (SPSS) 17.0 was used for statistical analysis. The chi-square test was used for enumeration data. One-way analysis of variance with Tukey's post hoc test was conducted for measurement data, and the *t* test was used for count data. P\<0.05 represented a statistically significant difference.

Results
=======

Comparisons of the basic data between the 2 groups of patients
--------------------------------------------------------------

There were no significant differences in gender, age, or course of hypertension parameters between the 2 groups, indicating that the groups were comparable ([Table 1](#t1-medscimonit-24-9259){ref-type="table"}).

Comparisons of SDRS scores between the 2 groups of patients
-----------------------------------------------------------

No significant change in SDRS scores was presented in the control group before and after treatment. However, we found the SDRS scores were significantly reduced at day 7, 14, 21 and 28 after the treatment, compared with that at day 0 (P\<0.05). Moreover, the scores of the patients in the treatment group were similar to those of the control group at day 21 after treatment ([Table 2](#t2-medscimonit-24-9259){ref-type="table"}).

Comparisons of the levels of serum inflammatory cytokines between the 2 groups of patients
------------------------------------------------------------------------------------------

Antihypertensive treatment significantly reduced levels of C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and matrix metalloproteinase-9 (MMP-9), as well as serum intercellular adhesion molecules (sICAM) and IL-1β, in both groups (P\<0.05). Additionally, after the treatment, serum inflammatory cytokines in the treatment group were significantly higher than those in the control group (P\<0.05) ([Table 3](#t3-medscimonit-24-9259){ref-type="table"}).

Comparison of blood pressure between the 2 groups
-------------------------------------------------

We then measured systolic blood pressures and diastolic blood pressures from both groups before and after the treatment (P\>0.05). The treatment significantly decreased SBP and SDP in both groups (P\<0.05). In addition, SBP and SDP were even further decreased in the control group after treatment compared with those in the treatment group (P\<0.05) ([Table 4](#t4-medscimonit-24-9259){ref-type="table"}). The blood pressure rhythm before treatment was significantly different between the 2 groups (P\<0.05), while the non-dipper blood pressure rhythm of patients in the treatment group was obviously higher than that of patients in the control group, indicating that chronic intractable insomnia affects the blood pressure rhythm and antihypertensive efficacy in patients. However, there were no significant differences between the 2 groups after the end of treatment ([Table 5](#t5-medscimonit-24-9259){ref-type="table"}).

Effects of intractable insomnia on blood pressure
-------------------------------------------------

To further assess the effects of insomnia on blood pressure and inflammatory cytokines, the treatment group was divided into an effective group and an ineffective group, according to the SDRS scores. Then, the blood pressure levels in the 2 groups were observed. The results showed that, after treatment for 21 days, SBP and DBP in the effective group were significantly lower than those in the ineffective group (P\<0.05), suggesting that treatment of intractable insomnia increases the efficacy of antihypertensive drugs ([Figure 1](#f1-medscimonit-24-9259){ref-type="fig"}).

Effects of intractable insomnia on inflammatory cytokines in patients
---------------------------------------------------------------------

We then assessed effects of treatment of intractable insomnia on the regulation of serum inflammatory cytokines CRP and TNF-α. Of note, treatment of intractable insomnia significantly reduced the levels in the effective group compared to those in the ineffective group (P\<0.05) ([Figures 2](#f2-medscimonit-24-9259){ref-type="fig"}, [3](#f3-medscimonit-24-9259){ref-type="fig"}). Similarly, the levels of other serum inflammatory cytokines (MMP-9, IL-1, IL-6, and sICAM) in patients in the effective insomnia treatment group were markedly lower than those in the ineffective insomnia treatment group (results not shown), suggesting that intractable insomnia affects the efficacy of antihypertensive drugs for serum inflammatory cytokines.

Discussion
==========

Insomnia primarily refers to a mental illness with common symptoms such as poor quality of sleep, short sleep duration, and frequent nocturnal awakenings \[[@b8-medscimonit-24-9259]\]. Frequent insomnia, also called chronic insomnia, can cause mental and physical problems, reduce work efficiency and quality of life, and affect the progression of other diseases and treatments \[[@b9-medscimonit-24-9259]\]. As the competition in modern society intensifies and the pressure of work increases, people's mental burdens are also increasing. The incidence of insomnia has been increasing year by year, and the average age of people affected is decreasing. A study has reported that about 10% of people worldwide have chronic insomnia \[[@b10-medscimonit-24-9259]\]. At present, there are 3 theories on the pathogenesis of insomnia: the psychogenic theory, the humor maladjustment theory, and the neurological theory \[[@b11-medscimonit-24-9259],[@b12-medscimonit-24-9259]\]. These 3 theories are associated with the occurrence of hypertension, and many people with chronic insomnia also have hypertension. Patients with chronic insomnia tend to be anxious and manic, and to have continuous sympathetic nervous excitement. The sympathetic hyper-excitability can contract blood vessels, increase blood flow resistance, and accelerate kidney, cerebral vessel, and other organ injuries. The humor maladjustment theory of insomnia involves the parasecretion of hypothalamic-pituitary-adrenocortical hormones, which results in dysregulation of water sodium and blood pressure, disorder of blood pressure rhythm, narrowing of day-to-night difference, and increased non-dipper proportion \[[@b13-medscimonit-24-9259],[@b14-medscimonit-24-9259]\]. Normally, the vagal and sympathetic excitements contain circadian rhythms, and the corresponding regulation of blood pressure also exhibits circadian rhythm. However, the disrupted sympathetic nerve rhythm of patients with chronic insomnia leads to disordered blood pressure in circadian rhythm (i.e., the formation of non-dipper blood pressure) \[[@b15-medscimonit-24-9259]\], and chronic intractable insomnia impairs the immune system. Patients with chronic intractable often have high levels of inflammatory cytokines. Meanwhile, the occurrence of hypertension is associated with various influencing factors. Increased vascular pressure in the brain, triggered by hypertension and insufficient blood supply to the heart and lungs, can also cause changes in nervousness, irritability, headaches, and other emotional changes, thus eventually leading to insomnia \[[@b16-medscimonit-24-9259]\]. Therefore, chronic intractable insomnia and hypertension interact with each other and co-occur \[[@b17-medscimonit-24-9259],[@b18-medscimonit-24-9259]\]. Previous finding revealed the effects of chronic intractable insomnia on hypertension. In the studies of Vgontzas et al., chronic insomnia was found to be an important risk factor for the development of hypertension \[[@b19-medscimonit-24-9259],[@b20-medscimonit-24-9259]\]. Previous evidence indicated the relationship between preoperative circadian blood pressure pattern and early postoperative course in patients undergoing coronary artery bypass graft (CABG) surgery \[[@b21-medscimonit-24-9259]\]. Furthermore, chemerin, which plays a role in inflammation and atherosclerosis, shows positive correlations with blood pressure \[[@b22-medscimonit-24-9259]\]. In the processes of the development and treatment of hypertensive disease, the crucial role of chronic intractable insomnia should be considered and provides clues to the appropriate treatment measures. However, the limitation of this study is that the exact mechanisms underlying the effect of chronic intractable insomnia on hypertension, as well as the potential signaling pathways, need to be further identified.

Conclusions
===========

Our data demonstrate that chronic intractable insomnia affects blood pressure and the therapeutic effect against hypertension, which provides a scientific basis for the therapy of hypertension.
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![Effect of estazolam (anti-intractable insomnia) on SBP (**A**) and DBP (**B**) in patients. The blood pressure was detected at 0, 7, 14, 21, and 28 days after treatment in the effective treatment group and ineffective treatment group.](medscimonit-24-9259-g001){#f1-medscimonit-24-9259}

![Effects of estazolam (anti-intractable insomnia) on CRP in patients. The differences in levels between the 2 groups before and after the treatment were determined.](medscimonit-24-9259-g002){#f2-medscimonit-24-9259}

![Effects of estazolam (anti-intractable insomnia) on TNF-α in patients. Differences in levels between the 2 groups before and after the treatment were determined.](medscimonit-24-9259-g003){#f3-medscimonit-24-9259}

###### 

Basic data of patients from 2 groups.

  Item                           Control group (n=124)   Treatment group (n=124)                                                                                                    P value
  ------------------------------ ----------------------- -------------------------------------------------------------------------------------------------------------------------- ---------
  Age                            57.8±13.1               60.2±10.7                                                                                                                  0.1154
  Male/Female                    83/41                   80/44                                                                                                                      0.6881
  Course of hypertension         1.0--3.5                1.1--4.2                                                                                                                   0.1150
  Chronic intractable insomnia   /                       Difficulty in falling asleep and maintaining sleep, psychological conflict, emotional instability, and excessive anxiety   /

###### 

Comparisons of SDRS scores between the 2 groups of patients (χ̄±s).

  Group                     0 d         7^th^ d                                                         14^th^ d                                                       21^st^ d                                                       28^th^ d
  ------------------------- ----------- --------------------------------------------------------------- -------------------------------------------------------------- -------------------------------------------------------------- --------------------------------------------------------------
  Control group (n=124)     16.9±9.6    15.2±9.2                                                        16.5±10.1                                                      16.8±9.1                                                       15.9±8.8
  Treatment group (n=124)   26.9±11.2   23.6±10.2[\*](#tfn1-medscimonit-24-9259){ref-type="table-fn"}   21.1±8.9[\*](#tfn1-medscimonit-24-9259){ref-type="table-fn"}   15.6±9.7[\*](#tfn1-medscimonit-24-9259){ref-type="table-fn"}   11.2±8.5[\*](#tfn1-medscimonit-24-9259){ref-type="table-fn"}

P\<0.05, compared with treatment at day 0.

###### 

Comparisons of the levels of serum inflammatory cytokines between the 2 groups of patients (χ̄±s).

  Item                                                     Control group   Treatment group                                                                   
  -------------------------------------------------------- --------------- ------------------------------------------------------------------ -------------- ---------------------------------------------------------------------------------------------------------------------
  CRP (mg/L)                                               5.21±1.07       2.66±1.14[\*](#tfn2-medscimonit-24-9259){ref-type="table-fn"}      6.91±1.76      2.87±1.34[\*](#tfn2-medscimonit-24-9259){ref-type="table-fn"}[\#](#tfn3-medscimonit-24-9259){ref-type="table-fn"}
  TNF-α (μg/L)                                             1.41±0.26       0.91±0.15[\*](#tfn2-medscimonit-24-9259){ref-type="table-fn"}      1.83±0.31      0.99±0.21[\*](#tfn2-medscimonit-24-9259){ref-type="table-fn"}[\#](#tfn3-medscimonit-24-9259){ref-type="table-fn"}
  IL-6 (ng/L)                                              186.7±17.21     103.21±19.84[\*](#tfn2-medscimonit-24-9259){ref-type="table-fn"}   209.58±29.34   108.4±19.47[\*](#tfn2-medscimonit-24-9259){ref-type="table-fn"}[\#](#tfn3-medscimonit-24-9259){ref-type="table-fn"}
  MMP-9 (pg/mL)                                            82.5±9.16       40.7±7.07[\*](#tfn2-medscimonit-24-9259){ref-type="table-fn"}      116.3±10.28    53.2±6.29[\*](#tfn2-medscimonit-24-9259){ref-type="table-fn"}[\#](#tfn3-medscimonit-24-9259){ref-type="table-fn"}
  Serum intercellular adhesion molecules (sICAM) (ng/mL)   381.5±105.2     329.4±121.3[\*](#tfn2-medscimonit-24-9259){ref-type="table-fn"}    437.3±142.9    342.2±131.6[\*](#tfn2-medscimonit-24-9259){ref-type="table-fn"}[\#](#tfn3-medscimonit-24-9259){ref-type="table-fn"}
  IL-1β (μg/L)                                             0.41±0.10       0.19±0.05[\*](#tfn2-medscimonit-24-9259){ref-type="table-fn"}      0.41±0.13      0.27±0.04[\*](#tfn2-medscimonit-24-9259){ref-type="table-fn"}[\#](#tfn3-medscimonit-24-9259){ref-type="table-fn"}

P\<0.05, after treatment *vs.* before treatment;

P\<0.05 control group *vs.* treatment group after treatment.

###### 

Comparison of blood pressure between the 2 groups of patients (χ̄±s, mmHg).

  Item    Control group   Treatment group                                                                                                                                                                                                                                      
  ------- --------------- --------------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------
  24-h    SBP             156.2±15.7                                                      140.1±10.8[\*](#tfn5-medscimonit-24-9259){ref-type="table-fn"}   163.6±11.5                                                                                                          144.6±12.5[\*](#tfn5-medscimonit-24-9259){ref-type="table-fn"}[\#](#tfn6-medscimonit-24-9259){ref-type="table-fn"}
  DBP     108.8±9.3       92.5±9.3[\*](#tfn5-medscimonit-24-9259){ref-type="table-fn"}    112.1±10.2                                                       104.7±7.9[\*](#tfn5-medscimonit-24-9259){ref-type="table-fn"}[\#](#tfn6-medscimonit-24-9259){ref-type="table-fn"}   
  Day     SBP             157.2±9.1                                                       142.6±8.3[\*](#tfn5-medscimonit-24-9259){ref-type="table-fn"}    159.2±10.4                                                                                                          145.7±9.5[\*](#tfn5-medscimonit-24-9259){ref-type="table-fn"}[\#](#tfn6-medscimonit-24-9259){ref-type="table-fn"}
  DBP     103.1±8.5       88.2±6.3[\*](#tfn5-medscimonit-24-9259){ref-type="table-fn"}    108.3±10.9                                                       98.7±10.2[\*](#tfn5-medscimonit-24-9259){ref-type="table-fn"}[\#](#tfn6-medscimonit-24-9259){ref-type="table-fn"}   
  Night   SBP             149.8±8.5                                                       139.5±8.8[\*](#tfn5-medscimonit-24-9259){ref-type="table-fn"}    154.7±9.7                                                                                                           143.5±7.7[\*](#tfn5-medscimonit-24-9259){ref-type="table-fn"}[\#](#tfn6-medscimonit-24-9259){ref-type="table-fn"}
  DBP     98.1±6.8        84.9±10.2[\*](#tfn5-medscimonit-24-9259){ref-type="table-fn"}   100.8±8.9                                                        91.2±7.98[\*](#tfn5-medscimonit-24-9259){ref-type="table-fn"}[\#](#tfn6-medscimonit-24-9259){ref-type="table-fn"}   

SBP -- systolic blood pressure; DBP -- diastolic blood pressure;

P\<0.05, after treatment *vs.* before treatment;

P\<0.05 control group *vs.* treatment group after treatment.

###### 

Comparison of the blood pressure rhythm between the 2 groups of patients.

  Group (n=124)     Before treatment   After treatment            
  ----------------- ------------------ ----------------- -------- ----
  Control group     68                 56                42       82
  Treatment group   85                 39                30       94
  P value           0.0264                               0.0932   
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